Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $15.58M rose 49.0% year over year, ahead of the +35.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 37.2% from the prior quarter. Over 3 fiscal years it compounded at +36.5% a year.
Context
- Stock-based compensation amounted to 83.3% of revenue in FY2025, up 31.4 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +49.0% holds above the trailing-twelve-month pace of +35.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 43.18M USD
- Year-over-year change
- +30.4%
- 4-year CAGR
- +30.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.18M | +30.4% |
| FY2024 | 2024-12-31 | 33.11M | +85.7% |
| FY2023 | 2023-12-31 | 17.83M | +5.1% |
| FY2022 | 2022-12-31 | 16.96M | +13.3% |
| FY2021 | 2021-12-31 | 14.98M | — |
Stock-Based Compensation vs competitors
How OCUL compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +35.8% is the 3rd highest of 10, against a peer median of +9.3%.
- Stock-based compensation amounts to 92.8% of revenue for OCUL, versus a peer median of 109.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $80.22M USD | +36.6% | +17.9% | 13.1% | |
| LTM Jun 2026 | $72M USD | -33.9% | +33.9% | 1.4% | |
| LTM Sep 2026 | $63.89M USD | +17.9% | -17.8% | — | |
| LTM Mar 2026 | $48.31M USD | +35.8% | +36.5% | 92.8% | |
| LTM Mar 2026 | $31.69M USD | -0.5% | +25.3% | 416.2% | |
| LTM Apr 2026 | $29.4M USD | +9.3% | +14.5% | 10.1% | |
| LTM Mar 2026 | CHF 18.42M CHF | +63.4% | +171.2% | 3653.8% | |
| LTM Mar 2026 | $11.78M USD | -34.6% | +16.2% | 4.4% | |
| LTM Mar 2026 | $9.22M USD | +22.1% | -9.9% | 206.5% | |
| LTM Mar 2026 | $5.14M USD | -37.3% | +4.9% | 1543.3% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $2.79M USD | — | — | — |
| Peer median (excluding OCUL) | — | +9.3% | +16.2% | 109.8% | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.98M | 16.96M | 17.83M | 33.11M | 43.18M |
| Change in Working Capital | (2.9M) | 1.35M | (7.41M) | (10.23M) | 7.71M |
| Accounts Receivables | (8.88M) | (190K) | (4.85M) | (6.21M) | 1.74M |
| Inventory | (49K) | (724K) | (331K) | (735K) | (524K) |
| Accounts Payables | 1.8M | (621K) | 583K | (318K) | (887K) |
| Other Working Capital | 4.24M | 2.88M | (2.81M) | (2.97M) | 7.38M |
| Other Non-Cash Items | (73.49M) | (8.99M) | (2.9M) | 32.16M | 5.84M |
| Operating Cash Flow | (65.55M) | (59.6M) | (70.23M) | (134.68M) | (204.88M) |
| Capital Expenditures | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (12.01M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 130K |
| Investing Cash Flow | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (11.88M) |
| Debt Repayment | (445K) | 0 | 56.35M | 316.35M | 0 |
| Common Stock Issued | 985K | 940K | 118.11M | 316.35M | 561.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.31M | 514K | (4.63M) | (300.6M) | 0 |
| Financing Cash Flow | 2.85M | 1.45M | 169.83M | 332.11M | 561.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (63.89M) | (61.86M) | 93.51M | 196.15M | 344.96M |
| Free Cash Flow | (66.74M) | (63.32M) | (76.32M) | (135.97M) | (216.89M) |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.